Jiangsu HengRui Medicine Co.Ltd.
Chidamide(Jiangsu HengRui Medicine Co., Ltd.)은 Diffuse Large B-Cell Lymphoma (DLBCL) 표적 치료제로, Diffuse Large B-Cell Lymphoma (DLBCL) 영역에서 개발·상용화 중입니다. 작용기전: Targeting the WNT/β-Catenin Pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 66건의 관련 임상이 등록되어 있습니다. 차별점: novel combinations with immunotherapy to harness the anti-tumor immune response.
Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL)
Recruiting
bispecific antibodies, and BV combined with ICE, ultimately achieving
vedotin (BV) maintenance therapy improves patie
linker and cap region structure, raising questions regarding their intrinsic Zn 2+ aff
retroviral therapy (ART) can control human immunodeficiency virus-1 (HIV-1) replication in
novel combinations with immunotherapy to harness the anti-tumor immune response
Targeting the WNT/β-Catenin Pathway
T cells infected with Vpx-complemented HIV-1 and found that the activation
apoptosis-associated proteins by decreasing BCL2 and increasing BAX
biomarkers
resistance to therapy in acute and chronic leukemias, lymphomas, and multiple myeloma
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Jiangsu HengRui Medicine Co.Ltd.
Chidamide(Jiangsu HengRui Medicine Co., Ltd.)은 Diffuse Large B-Cell Lymphoma (DLBCL) 표적 치료제로, Diffuse Large B-Cell Lymphoma (DLBCL) 영역에서 개발·상용화 중입니다. 작용기전: Targeting the WNT/β-Catenin Pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 66건의 관련 임상이 등록되어 있습니다. 차별점: novel combinations with immunotherapy to harness the anti-tumor immune response.
Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL)
Recruiting
bispecific antibodies, and BV combined with ICE, ultimately achieving
vedotin (BV) maintenance therapy improves patie
linker and cap region structure, raising questions regarding their intrinsic Zn 2+ aff
retroviral therapy (ART) can control human immunodeficiency virus-1 (HIV-1) replication in
novel combinations with immunotherapy to harness the anti-tumor immune response
Targeting the WNT/β-Catenin Pathway
T cells infected with Vpx-complemented HIV-1 and found that the activation
apoptosis-associated proteins by decreasing BCL2 and increasing BAX
biomarkers
resistance to therapy in acute and chronic leukemias, lymphomas, and multiple myeloma
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.